Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2019
Price : $35 *
At a glance
- Drugs Decitabine (Primary) ; MBG 453 (Primary) ; Spartalizumab (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 16 Jul 2019 Planned number of patients changed from 175 to 235.
- 16 Jul 2019 Planned End Date changed from 1 Apr 2020 to 1 Apr 2021.
- 18 Jun 2018 Number of arms has been changed from 3 to 5. Planned patient number has been changed from 70 to 175.